These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18483371)

  • 21. Enhanced expression of heat shock protein 27 following neoadjuvant hormonal therapy is associated with poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I; Fujisawa M
    Anticancer Res; 2006; 26(2B):1583-7. PubMed ID: 16619575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
    Figg WD; Dahut W; Duray P; Hamilton M; Tompkins A; Steinberg SM; Jones E; Premkumar A; Linehan WM; Floeter MK; Chen CC; Dixon S; Kohler DR; Krüger EA; Gubish E; Pluda JM; Reed E
    Clin Cancer Res; 2001 Jul; 7(7):1888-93. PubMed ID: 11448901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological evaluation of neoadjuvant peptide vaccination before radical prostatectomy for patients with localized prostate cancer.
    Noguchi M; Yao A; Harada M; Nakashima O; Komohara Y; Yamada S; Itoh K; Matsuoka K
    Prostate; 2007 Jun; 67(9):933-42. PubMed ID: 17440952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811.
    Kelly WK; Halabi S; Elfiky A; Ou SS; Bogart J; Zelefsky M; Small E;
    Cancer; 2008 Dec; 113(11):3137-45. PubMed ID: 18989865
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
    Fair WR; Aprikian AG; Cohen D; Sogani P; Reuter V
    Clin Invest Med; 1993 Dec; 16(6):516-22. PubMed ID: 8013156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).
    Schwaab T; Tretter CP; Gibson JJ; Cole BF; Schned AR; Harris R; Fisher JL; Crosby N; Stempkowski LM; Heaney JA; Ernstoff MS
    Prostate; 2006 May; 66(6):667-74. PubMed ID: 16425182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of vascular endothelial growth factor (VEGF)-A and its receptor in clinically localized prostate cancer: a prospective evaluation in 100 patients undergoing radical prostatectomy.
    Mao K; Badoual C; Camparo P; Delongchamps NB; Vieillefond A; Dinh-Xuan AT; Peyromaure M
    Can J Urol; 2008 Oct; 15(5):4257-62. PubMed ID: 18814815
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radical prostatectomy for high-risk prostate cancer: biochemical outcome.
    Kawamorita N; Saito S; Ishidoya S; Ito A; Saito H; Kato M; Arai Y
    Int J Urol; 2009 Sep; 16(9):733-8. PubMed ID: 19674167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pilot trial of adjuvant paclitaxel plus estramustine in resected high-risk prostate cancer.
    Cetnar JP; Malkowicz SB; Palmer SC; Wein AJ; Vaughn DJ
    Urology; 2008 May; 71(5):942-6. PubMed ID: 18279928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Randomized study of high-dose pulse calcitriol or placebo prior to radical prostatectomy.
    Beer TM; Myrthue A; Garzotto M; O'hara MF; Chin R; Lowe BA; Montalto MA; Corless CL; Henner WD
    Cancer Epidemiol Biomarkers Prev; 2004 Dec; 13(12):2225-32. PubMed ID: 15598784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear factor-kappaB-mediated transforming growth factor-beta-induced expression of vimentin is an independent predictor of biochemical recurrence after radical prostatectomy.
    Zhang Q; Helfand BT; Jang TL; Zhu LJ; Chen L; Yang XJ; Kozlowski J; Smith N; Kundu SD; Yang G; Raji AA; Javonovic B; Pins M; Lindholm P; Guo Y; Catalona WJ; Lee C
    Clin Cancer Res; 2009 May; 15(10):3557-67. PubMed ID: 19447876
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study of prostate specific antigen failure after radical prostatectomy for prostate cancer: a single center experience].
    Taue R; Takahashi M; Fukawa T; Koizumi T; Nakanishi R; Yamaguchi K; Yamamoto Y; Nakatsuji H; Kishimoto T; Izaki H; Oka N; Fukumori T; Kanayama HO
    Hinyokika Kiyo; 2009 Jan; 55(1):1-4. PubMed ID: 19227203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
    Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.
    Eder JP; Kantoff PW; Roper K; Xu GX; Bubley GJ; Boyden J; Gritz L; Mazzara G; Oh WK; Arlen P; Tsang KY; Panicali D; Schlom J; Kufe DW
    Clin Cancer Res; 2000 May; 6(5):1632-8. PubMed ID: 10815880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and pharmacodynamic evaluation of metronomic cyclophosphamide, celecoxib, and dexamethasone in advanced hormone-refractory prostate cancer.
    Fontana A; Galli L; Fioravanti A; Orlandi P; Galli C; Landi L; Bursi S; Allegrini G; Fontana E; Di Marsico R; Antonuzzo A; D'Arcangelo M; Danesi R; Del Tacca M; Falcone A; Bocci G
    Clin Cancer Res; 2009 Aug; 15(15):4954-62. PubMed ID: 19622584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Absence of Bcl-2 expression favors response to the short-term administration of diethylstilbestrol diphosphate in prostate Cancer.
    Nagaoka A; Kubota Y; Kurosu S; Nakada T; Bilim V; Tomita Y; Motoyama T
    Prostate; 2006 Dec; 66(16):1779-87. PubMed ID: 16998806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary levels of vascular endothelial growth factor in patients with prostate cancer as a predictor of disease progression.
    Miyake H; Muramaki M; Kurahashi T; Yamanaka K; Hara I
    Anticancer Res; 2005; 25(5):3645-9. PubMed ID: 16101195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant therapy before radical prostatectomy: where have we been? Where are we going?
    Pendleton J; Pisters LL; Nakamura K; Anai S; Rosser CJ
    Urol Oncol; 2007; 25(1):11-8. PubMed ID: 17208133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.